It’s a known problem, but treatment hasn’t improved in 20 years. Experts say it’s time for protocolized systems of care, they ...

Patients seen by a cardiologist after a heart attack or heart injury around the time of their major noncardiac surgery have ...

Citing lack of robust trial data, the committee offers algorithms and advice on care considerations in premenopausal individuals.

Guidelines emphasize single-pill combinations and deprescribing strategies to combat polypharmacy and hyperpolypharmacy in ...

From diabetes to cardiovascular disease, ignoring gender-specific risks may lead to delayed diagnosis and misdirected therapy in both women and men.

Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...

You are on scene with a patient who has sustained a significant injury; how do you decide whether to use red lights and ...

A research team led by Professors Joo-Yong Hahn, Young Bin Song, and Ki Hong Choi of the Division of Cardiology at Samsung ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...

Italy: Interventional cardiology in 2025 was shaped by a series of landmark randomized trials that refined procedural strategies, clarified long-term expectations, and accelerated the shift toward ...

The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...